Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Brandi

Showing results (81-90 of 246) with videos related to

Pageof 25
Sort By:
Oncology Reports|April 8, 2010
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review)Mariacristina Di Marco, Roberto Di Cicilia, Marina Macchini, et al.
Tumori|March 11, 2011
Durable complete response of hepatocellular carcinoma after metronomic capecitabineGiovanni Brandi, Francesco de Rosa, Luigi Bolondi, et al.
Annals of Palliative Medicine|May 12, 2021
Critical diagnostic delay associated with unusual presentation of hepatocellular carcinoma (HCC) with orbital metastases: a case reportDaria M Filippini, Alessandro Di Federico, Barbara Lenzi, et al.
The American Journal of Gastroenterology|November 11, 2005
Interactions between commensal bacteria and gut sensorimotor function in health and diseaseGiovanni Barbara, Vincenzo Stanghellini, Giovanni Brandi, et al.
Chemotherapy Research and Practice|February 2, 2012
Neoadjuvant treatment in rectal cancer: actual statusIngrid Garajová, Stefania Di Girolamo, Francesco de Rosa, et al.
Cancer Chemotherapy and Pharmacology|January 20, 2009
To widen the setting of cancer patients who could benefit from metronomic capecitabineMargherita Nannini, Elisabetta Nobili, Roberto Di Cicilia, et al.
Frontiers in Oncology|January 3, 2022
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, et al.
Pancreas|July 31, 2008
Exocrine-endocrine pancreatic cancer and alpha-fetoproteinGiovanni Brandi, Elisabetta Nobili, Elisa Capizzi, et al.
Expert Opinion on Investigational Drugs|December 14, 2020
Nivolumab: an investigational agent for the treatment of biliary tract cancerAlessandro Di Federico, Alessandro Rizzo, Angela Dalia Ricci, et al.
Expert Opinion on Investigational Drugs|November 20, 2021
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trialsAlessandro Di Federico, Alessandro Rizzo, Riccardo Carloni, et al.
Pageof 25

Showing results (81-90 of 246) with videos related to

Sort By:
Pageof 25
Oncology Reports|April 8, 2010
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review)Mariacristina Di Marco, Roberto Di Cicilia, Marina Macchini, et al.
Tumori|March 11, 2011
Durable complete response of hepatocellular carcinoma after metronomic capecitabineGiovanni Brandi, Francesco de Rosa, Luigi Bolondi, et al.
Annals of Palliative Medicine|May 12, 2021
Critical diagnostic delay associated with unusual presentation of hepatocellular carcinoma (HCC) with orbital metastases: a case reportDaria M Filippini, Alessandro Di Federico, Barbara Lenzi, et al.
The American Journal of Gastroenterology|November 11, 2005
Interactions between commensal bacteria and gut sensorimotor function in health and diseaseGiovanni Barbara, Vincenzo Stanghellini, Giovanni Brandi, et al.
Chemotherapy Research and Practice|February 2, 2012
Neoadjuvant treatment in rectal cancer: actual statusIngrid Garajová, Stefania Di Girolamo, Francesco de Rosa, et al.
Cancer Chemotherapy and Pharmacology|January 20, 2009
To widen the setting of cancer patients who could benefit from metronomic capecitabineMargherita Nannini, Elisabetta Nobili, Roberto Di Cicilia, et al.
Frontiers in Oncology|January 3, 2022
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, et al.
Pancreas|July 31, 2008
Exocrine-endocrine pancreatic cancer and alpha-fetoproteinGiovanni Brandi, Elisabetta Nobili, Elisa Capizzi, et al.
Expert Opinion on Investigational Drugs|December 14, 2020
Nivolumab: an investigational agent for the treatment of biliary tract cancerAlessandro Di Federico, Alessandro Rizzo, Angela Dalia Ricci, et al.
Expert Opinion on Investigational Drugs|November 20, 2021
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trialsAlessandro Di Federico, Alessandro Rizzo, Riccardo Carloni, et al.
Pageof 25